Business
ONWARD Medical Demonstrates Commercial Traction and Advances Pipeline in the First Half of 2025
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, The Netherlands, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces its results for the first half of 2025: Commercial tra
About this update from Onward Medical N.v.
[{"type":"image","alt":"ONWARD Medical NV","displaySize":"","headline":null,"caption":"ONWARD Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/ff435d5a4437f6b633ad80dab68096d0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CPLGUw1yVOurWsVIgzW3oQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ff435d5a4437f6b633ad80dab68096d0","width":300,"height":150}},"lazy":false},{"type":"text","content":"THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)","length":132,"tagName":"p"},{"type":"text","content":"EINDHOVEN, The Netherlands, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces its results for the first half of 2025:","length":357,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Commercial traction: The Company met its objective of 30 ARC-EX® Systems sold to US clinics in H1 as part of the planned phased launch, demonstrating strong commercial traction for this groundbreaking external spinal stimulation system.","length":236,"tagName":"p"}]},{"val":[{"type":"text","content":"Regulatory milestones: The Company submitted a 510(k) application to the US Food and Drug Administration (FDA) seeking clearance to expand the ARC-EX label to include home use. The Company also filed a CE Mark application to enable ARC-EX commercialization in Europe. Additionally, the FDA approved an investigational device exemption (IDE) for the ARC-IM® System, allowing the initiation of Empower BP, a global pivotal study designed to assess the safety and efficacy of the technology to address blood pressure instability after SCI.","length":536,"tagName":"p"}]},{"val":[{"type":"text","content":"Science & technology leadership: The Pathfinder2 study found that sustained access to ARC-EX Therapy can continue to drive improvements after one year of treatment. The ARC-IM platform reached a new milestone with the first human implant of the investigational ARC-IM Lumbar Lead, designed to help resto...